A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 455-460

  Sabbatini, Paul ^a   Sill, Michael W ^b,c   O'Malley, David ^d   Adler, Lisa ^e   Secord, Angeles Alvarez ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e Colorado Gynecologic Oncology Group PC ^*  (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Epithelial ovarian; Paclitaxel poliglumex

Indexed keywords

PACLITAXEL POLIGLUMEX;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DRUG DOSE REDUCTION; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SKIN MANIFESTATION; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; POLYGLUTAMIC ACID;

EID: 56749178680     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.07.049     Document Type: Article

References (30)

1. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
2. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
3. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
4. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 18 (2000) 1062-1067
5. ten Bokkel Huinik W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncol. 15 (1997) 2183-2193
6. Kayl A.E., and Meyers C.A. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr. Opin. Obstet. Gynecol. 18 (2006) 24-28
7. Li C. Poly(l-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 54 (2002) 695-713
8. Bonomi P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 7 (2007) 415-422
9. Singer J.W., Shaffer S., Baker B., Bernareggi A., Stromatt S., Nienstedt D., et al. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 16 (2005) 243-254
10. Shaffer S.A., Baker-Lee C., Kennedy J., Lai M.S., de Vries P., Buhler K., et al. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol. 59 (2007) 537-548
11. Li C., Newman R.A., Wu Q.P., Ke S., Chen W., Hutto T., et al. Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol. 46 (2000) 416-422
12. Robinson J.B., Singh D., Bodurka-Bevers D.C., Wharton J.T., Gershenson D.M., and Wolf J.K. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol. Oncol. 82 (2001) 550-558
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
14. Chen T.T. Ng TH. Optimal flexible designs in phase II clinical trials. Statist. Med. 17 (1998) 2301-2312
15. nd (2003), Chapman & Hall/CRC, Boca Raton
16. Arbuck SG, Ivy SP, Setser A, et al., The revised common toxicity criteria: version 2.0. CTEP Website. http://ctep.info.nih.gov.
17. Agresti A. Analysis of ordinal categorical data (1984), John Wiley & Sons, New York
18. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., and Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12 (1994) 1748-1753
19. Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., and Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol. Oncol. 79 (2000) 211-215
20. Trimble E.L., Adams J.D., Vena D., Hawkins M.J., Friedman M.A., Fisherman J.S., et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 11 (1993) 2405-2410
21. Markman M., Hakes T., Barakat R., Curtin J., Almadrones L., and Hoskins W. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. J. Clin. Oncol. 14 (1996) 796-799
22. Guastalla III J.P., and Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br. J. Cancer 89 Suppl 3 (2003) S16-S22
23. Eisenhauer E.A., Vermorken J.B., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann. Oncol. 8 (1997) 963-968
24. Markman M., Blessing J., Rubin S.C., Connor J., Hanjani P., and Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. 101 (2006) 436-440
25. Sabbatini P., Aghajanian C., Dizon D., Anderson S., Dupont J., Brown J.V., et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 22 (2004) 4523-4531
26. Kugler P., and Vornberger G. Renal cathepsin-B activities in rats after castration and treatment with sex hormones. Histochemistry 85 (1986) 157-161
27. Allievi C, Strepponi I, Bastrup U, Piazzoni S, Tavazzi R, Pisano G, et al., Biodistribution of paclitaxel poliglumex (PPX) in lung: Analysis of gender related alterations in a pre-clinical model. PROC ASCO 25:abs 17003, 2006.
28. Lin N.U., Parker L.M., Come S.E., Burstein H.J., Haldoupis M., Ryabin N., et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest. New Drugs 25 4 (2007) 369-375
29. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
30. Lee J.J., and Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 24 (2006) 1633-1642